Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T07:23:50.933Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanism of action of dextromethorphan/quinidine: comparison with ketamine

Published online by Cambridge University Press:  20 September 2013

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Abstract

ISSUE:Reports of rapid-onset but short-duration antidepressant effects in patients with treatment-resistant mood disorders after intravenous administration of ketamine have prompted efforts to find an agent with ketamine's properties that can be administered orally in repeated doses in order to sustain that action. One candidate for this is dextromethorphan, and here the pharmacologic mechanism of action is compared and contrasted with that of ketamine.

Type
Brainstorms
Information
CNS Spectrums , Volume 18 , Issue 5 , October 2013 , pp. 225 - 227
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Prescribing information, Nuedexta Package insert, 2013.Google Scholar
2.Pioro, EP, Brooks, BR, Cummings, J, etal. Safety, tolerability, and efficacy results trial of AVP-923 in PBA investigators dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010; 68(5): 693–702.CrossRefGoogle ScholarPubMed
3.Brooks, BR, Thisted, RA, Appel, SH, etal. AVP-923 ALS study group treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004; 63(8): 1364–1370.CrossRefGoogle Scholar
4.Stahl, SM. Stahl's Essential Psychopharmacology, 4th ed. New York: Cambridge University Press; 2013.Google Scholar
5.Roth, BL. Ki determinations, receptor binding profiles, agonist and/or antagonist functional data, HERG data, MDR1 data, etc. as appropriate was generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP), Contract # HHSN-271-2008-00025-C (NIMH PDSP). The NIMH PDSP is directed by Bryan L. Roth MD, PhD, at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscol at NIMH, Bethesda, MD, USA. For experimental details, please refer to the PDSP Web site: http://pdsp.med.unc.eduGoogle Scholar
6.Stahl, SM. Mechanism of action of ketamine. CNS Spectr. 2013; 18: 171–174.CrossRefGoogle ScholarPubMed
7.Bunney, BG, Bunney, WE. Rapid-acting antidepressant strategies: mechanisms of action. Int J Neuropsychopharmacol. 2012; 15: 695–713.Google ScholarPubMed
8.Ibrahim, L, DiazGranados, N, Franco-Chaves, J, etal. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012; 37(6): 1526–1533.CrossRefGoogle ScholarPubMed
9.Hayashi, T, Stahl, SM. Sigma 1 receptor and its role in the treatment of mood disorders. Drugs of the Future. 2009; 34: 137–146.CrossRefGoogle Scholar
10.Stahl, SM. The sigma enigma: can sigma receptors provide a novel target for disorders of mood and cognition? J Clin Psychiatry. 2008; 69: 1673–1674.CrossRefGoogle ScholarPubMed